GLUE241220C22500
- 0.50
- 0.000.00%
Monte Rosa Therapeutics Newsroom
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Owning 47% Shares,institutional Owners Seem Interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $15
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $14
Express News | Monte Rosa Therapeutics Inc : JP Morgan Raises Target Price to $15 From $7
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
Optimistic Outlook and Buy Rating on Monte Rosa Therapeutics Due to Promising Clinical Progress and Strategic Collaborations
Monte Rosa Therapeutics Reports Q3 EPS (29c), Consensus (49c)
Monte Rosa Therapeutics: Q3 Earnings Snapshot
Monte Rosa Therapeutics | 10-Q: Q3 2024 Earnings Report
Monte Rosa Therapeutics 3Q Loss/Shr 29c >GLUE
Monte Rosa Therapeutics 3Q Rev $9.22M >GLUE
Monte Rosa Therapeutics | 8-K: Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Earnings Flash (GLUE) MONTE ROSA THERAPEUTICS Posts Q3 Loss $-0.29 Per Share
Express News | Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Monte Rosa Therapeutics Q3 Pretax Profit USD -23.788 Million
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's Is How to Trade
Monte Rosa Therapeutics Price Target Raised to $20 From $16 at Piper Sandler
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $17